Neurodevelopmental epilepsies (NDEs) represent a compelling frontier for gene therapy due to their well-defined genetic basis, early onset, profound unmet need, and the potential to intervene before irreversible neurological damage occurs. Unlike acquired epilepsies, NDEs are caused by monogenic mutations that disrupt specific molecular pathways in the brain, making them ideal targets for precision genetic medicine approaches.
This page provides a comprehensive overview of the major gene therapy modalities being developed for NDEs including Dravet syndrome (SCN1A), Angelman syndrome (UBE3A), KCNQ2 encephalopathy, CDKL5 deficiency disorder, STXBP1 encephalopathy, and related disorders.
1. Monogenic basis: Most NDEs are caused by mutations in a single gene, making the therapeutic target unambiguous:
2. Early intervention opportunity: NDEs manifest in infancy or early childhood, before the full extent of developmental damage occurs. Early gene therapy could potentially prevent or reduce the severity of cognitive decline, behavioral disorders, and refractory seizures.
3. Haploinsufficiency mechanism: Most NDEs result from haploinsufficiency — where one functional allele cannot produce sufficient protein. This creates a clear therapeutic window: restoring expression to 70-100% of normal levels may be sufficient for clinical benefit.
4. High unmet need: 30-50% of NDE patients are refractory to all available anti-seizure medications. Current standards of care (fenfluramine, CBD, stiripentol, clobazam) manage but do not cure the disease.
| Disease | Gene | Prevalence | Key Features | Gene Therapy Status |
|---|---|---|---|---|
| Dravet syndrome | SCN1A | 1:15,000-20,000 | Onset 6-18 months, multiple seizure types, SUDEP risk | Phase 1/2 (STK-001 ASO), Preclinical (ETX101 AAV) |
| Angelman syndrome | UBE3A | 1:10,000-20,000 | Severe ID, ataxia, happy demeanor, 80% epilepsy | Phase 1/2 (GTX-102 ASO) |
| KCNQ2 encephalopathy | KCNQ2 | 1:50,000-100,000 | Neonatal seizures, variable outcome | Preclinical |
| CDKL5 deficiency disorder | CDKL5 | 1:40,000-60,000 | Early onset, refractory seizures, severe ID | Preclinical |
| STXBP1 encephalopathy | STXBP1 | 1:100,000-150,000 | Multiple seizure types, severe ID | Preclinical |
| SLC6A1-related epilepsy | SLC6A1 | 1:100,000 | Myoclonic-atonic seizures, variable phenotype | Preclinical |
| GABRB3-related epilepsy | GABRB3 | 1:50,000-100,000 | Absence, myoclonic seizures, ASD comorbidity | Preclinical |
| PCDH19 epilepsy | PCDH19 | 1:50,000 | X-linked dominant, clustering seizures | Preclinical |
ASOs are short, synthetic DNA-like molecules (typically 12-30 nucleotides) that bind to specific messenger RNA (mRNA) sequences via Watson-Crick base pairing and modulate gene expression. ASOs can work through several mechanisms[1]:
Mechanisms of Action:
NDE Applications:
| Drug | Company | Target | Mechanism | Phase |
|---|---|---|---|---|
| STK-001 | Stoke Therapeutics | SCN1A | Allele-selective knockdown of mutant allele | Phase 1/2 |
| STK-002 | Stoke Therapeutics | SCN1A | Same as STK-001, higher dose | Phase 1 |
| GTX-102 | GeneTx/Ultragenyx | UBE3A-ATS | Inhibit antisense transcript, reactivate paternal allele | Phase 1/2 |
Clinical Advantages:
Clinical Limitations:
Adeno-associated virus (AAV) vectors deliver functional gene copies directly to target cells, providing potentially durable or permanent therapeutic benefit from a single administration[3].
AAV Biology:
NDE Applications:
| Program | Company | Target | Approach | Stage |
|---|---|---|---|---|
| ETX101 | Encoded Therapeutics | SCN1A | CRISPRa upregulation of WT allele | Preclinical (IND-enabling) |
| AAV-SCN1A | Roche/Neurocrine | SCN1A | Full gene delivery | Discovery |
| CDKL5 program | Vigonvita | CDKL5 | Gene replacement | Preclinical |
| KCNQ2 program | Academic (CHOP) | KCNQ2 | Gene replacement | Preclinical |
| STXBP1 program | Various academic | STXBP1 | Gene replacement | Preclinical |
Technical Challenges:
AAV Delivery Routes:
| Route | Description | Advantages | Limitations |
|---|---|---|---|
| Intra-cisterna magna (ICM) | Injection into cisterna magna (below cerebellum) | Direct CNS access, bypasses BBB, high spinal cord/cortex coverage | Surgical procedure, requires anesthesia |
| Intra-cerebroventricular (ICV) | Injection into lateral ventricles | Direct CSF access, established neurosurgical approach | Limited parenchymal distribution |
| Intravenous (IV) | Systemic administration | Non-invasive, systemic coverage | Requires BBB-crossing serotype, high liver tropism |
| Intraparenchymal | Direct brain injection | Precise targeting, high local concentration | Limited distribution, multiple injections needed |
CRISPR-Cas systems enable precise editing of the genome or targeted modulation of gene expression. Multiple CRISPR-based strategies are being developed for NDEs.
CRISPR-Activation (CRISPRa):
Unlike traditional CRISPR-Cas9 which cuts DNA, CRISPRa uses a catalytically dead Cas9 (dCas9) fused to transcriptional activation domains (VP64, p65, Rta). This complex is guided by an sgRNA to the promoter region of a target gene, where it recruits endogenous transcriptional machinery to increase expression.
Advantages for NDEs:
Example: ETX101 for Dravet syndrome
Encoded Therapeutics' ETX101 uses AAV9-delivered CRISPRa to upregulate the wild-type SCN1A allele. The CRISPRa complex is designed to bind to the SCN1A promoter region, dramatically increasing transcription from the healthy allele, thereby addressing haploinsufficiency.
Base Editing:
Base editors (CBE, ABE) make single-nucleotide changes without double-strand breaks. For NDEs caused by missense mutations (~40% of Dravet syndrome), base editing could correct the underlying mutation directly.
Prime Editing:
Prime editors can make all 12 types of point mutations, as well as small insertions and deletions, without double-strand breaks. This offers broader variant coverage than base editing for diseases with diverse mutation spectra.
Delivery challenge: Both base and prime editing require delivery of the editing machinery (Cas9 variant + guide RNA ± template) which exceeds AAV capacity in most cases. Solutions include:
RNA editing technologies modify RNA transcripts rather than DNA, offering a potentially safer and more flexible approach to gene therapy.
ADAR-Mediated Editing:
Uses engineered guide RNAs that recruit the endogenous ADAR (Adenosine Deaminases Acting on RNA) enzyme to convert adenosine to inosine (A→I) in target transcripts. This can correct point mutations where A→G correction is needed.
Advantages:
Companies developing CNS RNA editing:
Gene Replacement: Delivering a functional copy of the disease gene. Suitable for:
Gene Upregulation: Increasing expression of the endogenous wild-type allele. Suitable for:
| Approach | Example | Mechanism |
|---|---|---|
| Gene replacement | AAV-KCNQ2, AAV-STXBP1 | Deliver functional gene copy |
| Gene upregulation | CRISPRa-ETX101 | Increase endogenous WT expression |
| Allele-selective | STK-001 | Reduce mutant allele, preserve WT |
| Splice-switching | STK-001 (TANGO) | Skip mutant exon, produce WT protein |
| Feature | ASO | AAV Gene Therapy | CRISPRa | Base/Prime Editing | RNA Editing |
|---|---|---|---|---|---|
| Duration | 2-4 months | Years | Years | Permanent | Days-weeks |
| Redosability | Yes | Limited | Limited | Limited | Yes |
| Gene size limits | None | ~4.7kb | ~4.7kb | ~4.7kb | None |
| Clinical validation | High (SMA, ALS) | Moderate | Early | Early | Minimal |
| Delivery | Intrathecal | ICV/ICM/IV | ICV/ICM | Various | Various |
| Off-target risk | Splice off-target | Insertional (low) | Transcriptional | Genomic | RNA off-target |
| BBB crossing | Requires IT delivery | Requires enhanced serotype | Requires delivery vehicle | Requires delivery vehicle | Requires delivery vehicle |
| Single dose potential | No | Yes | Yes | Yes | No |
For an up-to-date view of clinical trials for gene therapy approaches to neurodevelopmental epilepsies, see the main therapeutic hub page: AAV Gene Therapy for Neurodevelopmental Epilepsy — Competitive Landscape.
Key Active Trials:
| Trial | NCT | Drug | Company | Phase | Status |
|---|---|---|---|---|---|
| CONNECT1 | NCT04414332 | STK-001 | Stoke Therapeutics | Phase 1/2 | Recruiting |
| CONNECT2 | — | STK-002 | Stoke Therapeutics | Phase 1 | Phase 1 |
| — | NCT04259281 | GTX-102 | GeneTx/Ultragenyx | Phase 1/2 | Active |
| — | — | ETX101 | Encoded Therapeutics | Preclinical | IND-enabling |
Bennett, C.F., Krainer, A.R., & Cleveland, D.W. Antisense oligonucleotide therapies for neurodegenerative diseases. Annual Review of Pharmacology and Toxicology. 2019. ↩︎
Miller, A.R., et al. Allele-selective reduction of toxic sodium channel expression with antisense oligonucleotides. Science Translational Medicine. 2023. ↩︎
Mendell JR, et al. AAV gene therapy for monogenic neurological disorders. Nature Reviews Disease Primers. 2020. ↩︎